SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
Website: www.sinobiopharm.com
(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

APPLICATION FOR CLINICAL TRIAL ON TQB3205 "PAN-KRAS INHIBITOR" APPROVED BY THE NMPA

The board of directors (the "**Board**") of Sino Biopharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces that TQB3205 "pan-KRAS inhibitor", a national Category 1 innovative drug independently developed by Chia Tai Tianqing Pharmaceutical Group Co. Ltd. ("**CTTQ**", a subsidiary of the Group), has received the clinical trial approval from China's National Medical Products Administration (NMPA) for the intended treatment of advanced malignant tumors.

TQB3205 is an oral pan-KRAS inhibitor. Its core mechanism of action involves the binding to multiple KRAS-mutant proteins with high affinity, thereby blocking RAS activation by inhibiting SOS1-mediated nucleotide exchange in KRAS, and in turn suppressing the phosphorylation of downstream ERK. Accordingly, the process effectively inhibits the proliferation of various KRAS-mutant tumor cells.

The KRAS gene is the most frequently mutated gene within the RAS family. Approximately 30% of all cancer cases worldwide are associated with RAS gene mutations, with KRAS mutations accounting for 85% of all RAS mutations. Such mutations are prevalent in various cancers, including pancreatic cancer (90%), colorectal cancer (30%-50%), and non-small cell lung cancer (15%-20%)[1-2]. However, KRAS mutation subtypes vary significantly across different tumor types, with common variants including G12C, G12V, G12D, and G13D[3-4]. Currently, all five KRAS inhibitors approved for marketing worldwide only target the G12C mutation subtype.

The Group's jointly developed KRAS G12C inhibitor, garsorasib (trade name: Anfangning (安方寧)), received marketing approval from China's NMPA in November 2024. Nonetheless, clinical needs in the field of KRAS remain highly unmet, thus necessitating pan-KRAS inhibitors which are capable of covering a broader range of mutation subtypes. The Group is committed to accelerating the clinical development of TQB3205 to overcome existing treatment limitations and provide novel therapeutic options for a broader patient population with advanced malignant tumors harboring KRAS mutations.

Sources:

[1] Wang Y, You M, Wang Y. Alternative splicing of the K-RAS gene in mouse tissues and celllines[J]. Exp Lung Res, 2001, 27(3): 255-267.

[2] Parikh K, Banna G, Liu SV, et al. Drugging KRAS: Current perspectives and state-of-art review[J]. J Hematol Oncol, 2022, 15(1): 152.

[3] Kulkarni AM, Kumar V, Parate S, et al. Identification of new KRAS G12D inhibitors through computer-aided drug discovery methods[J]. Int J Mol Sci, 2022, 23(3): 1309.

[4] O'Bryan JP. Pharmacological targeting of RAS: Recent success with direct inhibitors[J].Pharmacol Res, 2019, 139: 503-511.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 11 March 2026

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.